替吉奥联合吉西他滨或长春瑞滨治疗晚期乳腺癌的疗效分析

Clinical Efficacy of Tegafur Gimeracil Oteracil Potassium Capsule Plus Gemcitabine or Vinorelbine in Treatment of Advanced Breast Cancer

目的观察分析替吉奥联合吉西他滨或长春瑞滨治疗晚期乳腺癌的疗效和安全性。方法选取笔者医院经病理确诊的47例晚期乳腺癌患者,随机分为吉西他滨组及长春瑞滨组。吉西他滨组24例:吉西他滨1000mg/m^2静脉滴注30min,第1、8天;替吉奥胶囊80mg/m^2,每日分早晚2次,于餐后口服,连续口服2周;长春瑞滨组23例:长春瑞滨(盖诺,江苏豪森药业生产)25mg/m^2静脉滴注30min,第1、8天;替吉奥用法用量同吉西他滨组。以上两方案均以3周为1个周期。结果 47例均纳入分析,吉西他滨组与长春瑞滨组的有效率分别为37.5%、43.4%,疾病控制率是75%、69.5%,中位疾病进展时间分别为5.3个月及4.9个月,中位生存期均是12个月,两组间比较差异无统计学意义(P>0.05)。两组主要不良反应多为轻度,重度不良反应主要为骨髓抑制,两组重度不良反应的发生率经比较,差异无统计学意义(P>0.05)。结论替吉奥联合吉西他滨或长春瑞滨治疗晚期乳腺癌临床疗效好,不良反应可耐受。

Objective To assess and analyze the efficacy and safety of tegafur gimeracil oteraeil potassium capsule plus gemcitabine or vinorelbine for the treatment of advanced breast cancer. Methods Totally 47 patients pathologically diagnosed advanced breast cancer were randomly divided into two groups： the gemcitabine group （24 cases） and the vinorelbine group （23 cases）. The gemcitabine group was treated with gemeitabin 1000mg/m2 for 30 minutes on day 1, 8 and Tegafur Gimeraeil Oteracil Potassium Capsule （ 80mg/m2 ） orally, for 14 days continuously. The vinorelbine group was applied with vinorelbine 25mg/m2 for 30 minutes on day 1, 8 and Tegafur Gimeracil Oteracil Potassium Capsule of the same dose and duration. The two groups both used three weeks as a cycle. Results All 47 patients were included for analysis. The response rates were 37.5% and 43.4% , overall disease control rates were 75% and 69.5% , mean pro- gression free survival time was 5.3 months and 4.9 months, mean survival time was 12 months and 12 months, respectively. There＇s no significant difference between the two groups. In both two groups ,most adverse effects were mild and severe adverse effects happened in bone marrow. There was no statistically difference in the incidence of severe adverse effects between them. Conclusion Tegafur gime- racil oteraeil potassium capsule plus gemcitabine or vinorelbine for the treatment of advanced breast cancer is effective and safe.